Temporal Trends and Socioeconomic Determinants of Cytoreductive Nephrectomy Utilization for Metastatic Renal Cell Carcinoma in the USA
European Urology Focus · 2025
DOI: 10.1016/j.euf.2025.05.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Urology Focus, 2025. Verfasst von Stepan M Esagian und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, NYC Health + Hospitals/Jacobi, Albert Einstein College of Medicine, Bronx, NY, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Nephrectomy, Cytoreduction Surgical Procedures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: The evolving treatment landscape in metastatic renal cell carcinoma (mRCC) since the advent of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has rendered the role of cytoreductive nephrectomy (CN) unclear. We sought to quantify CN utilization in the USA over the past two decades and assess factors that affect access to CN. METHODS: We analyzed the National Inpatient Sample database from 2006 to 2021, identifying mRCC patients who underwent CN using International Classification of Diseases (ICD)-9 and ICD-10 codes. Annual CN utilization rates were calculated and stratified by demographic and socioeconomic factors. Univariable and multivariable logistic regression analyses, guided by directed acyclic graphs, were performed to assess the factors influencing CN utilization. KEY FINDINGS AND LIMITATIONS: CN utilization declined significantly in 2021 compared with that in 2006 (8.7% vs 15.8%; odds ratio [OR] 0.51, 95% confidence interval [CI] 0.42-0.61), a trend observed across all demographic groups. Reduced CN utilization was associated with Black (OR 0.70, 95% CI 0.64-0.76) and Hispanic (OR 0.87, 95% CI 0.80-0.95) race, female gender (OR 0.94, 95% CI 0.90-0.98), Medicare (adjusted OR [aOR] 0.69, 95% CI 0.64-0.73) or Medicaid (aOR 0.59, 95% CI 0.54-0.64) insurance, lower income (aOR 0.84, 95% CI 0.78-0.90), Southern US location (aOR 0.83, 95% CI 0.74-0.93), and treatment at small (aOR 0.57, 95% CI 0.51-0.63) or rural (aOR 0.32, 95% CI 0.26-0.38) hospitals. CN utilization declined further in the ICI (2018-2021) era compared with the TKI era (2006-2017; OR 0.69, 95% CI 0.64-0.75). CONCLUSIONS AND CLINICAL IMPLICATIONS: CN utilization has decreased progressively in the USA, coinciding with the emergence of novel systemic therapies. Several demographic and socioeconomic factors are associated with differential CN utilization. These findings underscore the need for further research to clarify the role of CN in the evolving mRCC therapeutic landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, NYC Health + Hospitals/Jacobi, Albert Einstein College of Medicine, Bronx, NY, USA.
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Hous…
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Departments of Oncology and Urology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, USA.
- Department of Medicine, NYC Health + Hospitals/Jacobi, Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: Dimitris.g.makrakis@gmail.com.
Zitieren
APA
Esagian, S. M., Msaouel, P., Karam, J. A., Gartrell, B. A., & Makrakis, D. (2025). Temporal Trends and Socioeconomic Determinants of Cytoreductive Nephrectomy Utilization for Metastatic Renal Cell Carcinoma in the USA. European Urology Focus. https://doi.org/10.1016/j.euf.2025.05.016
Vancouver
Esagian SM, Msaouel P, Karam JA, Gartrell BA, Makrakis D. Temporal Trends and Socioeconomic Determinants of Cytoreductive Nephrectomy Utilization for Metastatic Renal Cell Carcinoma in the USA. European Urology Focus. 2025. doi:10.1016/j.euf.2025.05.016
BibTeX
@article{Esagian2025,
author = {Esagian, Stepan M and Msaouel, Pavlos and Karam, Jose A and Gartrell, Benjamin A and Makrakis, Dimitrios},
title = {Temporal Trends and Socioeconomic Determinants of Cytoreductive Nephrectomy Utilization for Metastatic Renal Cell Carcinoma in the USA},
journal = {European Urology Focus},
year = {2025},
doi = {10.1016/j.euf.2025.05.016}
}
EUVIMED